先進診断システム探索研究部門

Motoko Shinohara

  (篠原 基子)

Profile Information

Affiliation
Center for Infectious Disease Research, Fujita Health University

Researcher number
71013744
ORCID ID
 https://orcid.org/0000-0001-7111-8012
J-GLOBAL ID
202401001157209444
researchmap Member ID
R000079950

Papers

 13
  • Akiho Yagi, Motoko Shinohara, Yusuke Minato, Ryuji Uchida
    Antimicrobial Agents and Chemotherapy, Feb 19, 2026  
  • Kotaro Sawai, Marie Ikai, Motoko Shinohara, Yukiko Nishiuchi, So Fujiyoshi, Yohei Doi, Tomotada Iwamoto, Kentaro Arikawa, Fumito Maruyama, Yusuke Minato
    Oct 13, 2025  
  • Takeshi Nakaya, Miyuki Yabe, Ellene H Mashalidis, Toyotaka Sato, Kazuki Yamamoto, Yuta Hikiji, Akira Katsuyama, Motoko Shinohara, Yusuke Minato, Satoshi Takahashi, Motohiro Horiuchi, Shin-Ichi Yokota, Seok-Yong Lee, Satoshi Ichikawa
    Nature communications, 13(1) 7575-7575, Dec 20, 2022  
    The development of new antibacterial drugs with different mechanisms of action is urgently needed to address antimicrobial resistance. MraY is an essential membrane enzyme required for bacterial cell wall synthesis. Sphaerimicins are naturally occurring macrocyclic nucleoside inhibitors of MraY and are considered a promising target in antibacterial discovery. However, developing sphaerimicins as antibacterials has been challenging due to their complex macrocyclic structures. In this study, we construct their characteristic macrocyclic skeleton via two key reactions. Having then determined the structure of a sphaerimicin analogue bound to MraY, we use a structure-guided approach to design simplified sphaerimicin analogues. These analogues retain potency against MraY and exhibit potent antibacterial activity against Gram-positive bacteria, including clinically isolated drug resistant strains of S. aureus and E. faecium. Our study combines synthetic chemistry, structural biology, and microbiology to provide a platform for the development of MraY inhibitors as antibacterials against drug-resistant bacteria.
  • Shintaro Kusaka, Kazuki Yamamoto, Motoko Shinohara, Yusuke Minato, Satoshi Ichikawa
    Bioorganic & medicinal chemistry, 73 117011-117011, Nov 1, 2022  
    The total synthesis of capuramycin (1), which is a promising anti-tubercular antibiotics, has been accomplished using Ferrier-type I reaction as a key step. This total synthesis is an alternative approach to the synthesis of capuramycin and its analogues. The 3'-O-demethyl analogue (2), which exhibits an equivalent antibacterial activity as capuramycin (1) against Mycobacterium smegmatis and Mycobacterium avium, is suggested to have potential as a lead structure of capuramycin analogues because 2 is more accessible from a synthetic view point.
  • Shintaro Kusaka, Kazuki Yamamoto, Motoko Shinohara, Yusuke Minato, Satoshi Ichikawa
    Bioorganic & medicinal chemistry, 65 116744-116744, Jul 1, 2022  
    It is important to understand and control the biologically active conformation in medicinal chemistry. Muraymycins and caprazamycins, which are strong inhibitors of MraY, are promising antibacterial agents with a novel mode of action. Focusing on a sugar puckering and a dihedral angle ϕ of the uridine moiety of these natural products, LNA/BNA-type 5'-O-aminoribosyluridine analogues, whose puckering of the ribose moiety are completely restricted to the N-type, were designed and synthesized as simplified MraY inhibitors. Their conformation-activity relationship was further investigated in details. The conformation-activity relationship analysis investigated in this study could be a general guideline for simplification and rational drug design of MraY inhibitory nucleoside natural products.